Ashley Cordova, CEO of Novocure (NVCR), joins Trading 360 after ringing the opening bell at the Nasdaq. Novocure “targets the electrical properties of cells” to fight aggressive cancers. “We are focused on extending survival,” she says, and notes recent FDA approval for lung cancer treatment and clinical trials in pancreatic and brain cancers. She also discusses the company’s balance sheet, R&D investment, and potential partnerships.